Kurt Prins, M.D., Ph.D.

Home
Research & Reports
About Our Research
Previously Funded Researchers
Kurt Prins, MD, PhD

Research Project:
Treating Right Heart Dysfunction to Improve Outcomes in PAH

Grant Awarded:

Innovation Award

Research Topics:

basic biologic mechanisms
combination therapies experimental therapeutics

Research Disease:

pulmonary vascular disease

We have shown small molecule inhibition of WNK1 signaling prevents metabolic derangements in the monocrotaline model of pulmonary arterial hypertension. In particular, we showed WNK1 inhibition prevented pathological increase in glucose uptake, activated AMP kinase signaling, which then manifested as augmented fatty acid metabolism. Importantly, these data suggest that WNK1 may be a target for RV dysfunction in pulmonary arterial hypertension, a currently untreatable consequence of pulmonary arterial hypertension.

Update: We have shown small molecule inhibition of WNK1 enhances RV metabolism and augments RV function in rodent pulmonary arterial hypertension.

Page last updated: June 7, 2024

Join the Patient & Caregiver Network

End Youth Vaping

10 Tips to Protect Yourself from Unhealthy Air

State of the Air Key Findings

Become an Advocate

Events Near You

Kurt Prins, MD, PhD

Your Gift, TRIPLED

Make a Donation

Become a Lung Health Insider

Select Your Location

Change Language

Lung HelpLine

1-800-LUNG-USA